265 studies found for:    Open Studies | "Carcinoma, Renal Cell"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Carcinoma, Renal Cell"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting Immunotherapy Study for Metastatic Renal Cell Cancer
Conditions: Metastatic Renal Cell Carcinoma;   Metastatic Clear-cell Renal Cancer;   Recurrent Renal Cell Carcinoma;   Refractory Renal Cell Carcinoma;   Metastatic Kidney Cancer
Intervention: Biological: HyperAcute®-Renal (HAR) Immunotherapy
2 Recruiting AMG 172 First in Human Study in Patients With Kidney Cancer
Conditions: Renal Cell Adenocarcinoma;   Clear Cell Renal Carcinoma;   Clear Cell Renal Cell Carcinoma;   Renal Cell Carcinoma
Intervention: Drug: AMG 172
3 Recruiting A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
Conditions: Carcinoma, Renal Cell;   Renal Cell Carcinoma With Clear Cell Histology;   Renal Cell Carcinoma With Non-Clear Cell Histology;   Renal Cell Carcinoma of Papillary Histology
Intervention: Drug: AGS-16C3F
4 Recruiting Bevacizumab With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma
Interventions: Biological: bevacizumab;   Biological: anti-endoglin monoclonal antibody TRC105;   Other: laboratory biomarker analysis;   Other: pharmacological study
5 Recruiting Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Biological: ziv-aflibercept;   Other: laboratory biomarker analysis
6 Recruiting Pazopanib in Treating Patients With Metastatic Non-Clear Cell Kidney Cancer
Conditions: Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma
Intervention: Drug: pazopanib hydrochloride
7 Recruiting Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: panobinostat;   Drug: everolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: liquid chromatography;   Other: mass spectrometry;   Other: enzyme-linked immunosorbent assay;   Other: immunohistochemistry staining method
8 Unknown  Treatment of Patients With Advanced Renal Cancer With a Radio-labeled Antibody, Yttrium-90 Conjugated Chimeric G250
Conditions: Renal Cell Carcinoma;   Kidney Neoplasm;   Renal Cancer;   Kidney Cancer
Intervention: Drug: Yttrium-90 conjugated chimeric G250 (90Y-cG250)
9 Recruiting First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
Conditions: Locally Advanced and/or Metastatic Renal Cell Carcinoma;   Carcinoma, Renal Cell;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Pazopanib
10 Recruiting Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer
Conditions: Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Genetic: mutation analysis;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Drug: sunitinib malate;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
11 Recruiting Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)
Conditions: Advanced Renal Cell Carcinoma;   Renal Cell Carcinoma;   Metastatic Renal Cell Carcinoma
Interventions: Drug: Standard Treatment;   Biological: AGS-003
12 Not yet recruiting Perfusion CT in Predicting Response to Treatment in Patients With Advanced Kidney Cancer
Conditions: Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: perfusion;   Procedure: computed tomography;   Other: laboratory biomarker analysis
13 Recruiting Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: pazopanib hydrochloride;   Other: laboratory biomarker analysis;   Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Other: pharmacogenomic studies
14 Not yet recruiting Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Radiation: stereotactic body radiation therapy;   Drug: cyclophosphamide;   Biological: therapeutic autologous lymphocytes;   Other: laboratory biomarker analysis
15 Recruiting Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Biological: AdGMCAIX-transduced autologous dendritic cells;   Biological: therapeutic autologous dendritic cells;   Other: laboratory biomarker analysis
16 Recruiting Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: cabozantinib-s-malate;   Drug: sunitinib malate;   Other: laboratory biomarker analysis
17 Recruiting Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer;   Stage III Renal Cell Cancer
Interventions: Drug: pazopanib hydrochloride;   Procedure: therapeutic conventional surgery
18 Recruiting Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
Conditions: Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Biological: trebananib;   Biological: bevacizumab;   Drug: pazopanib hydrochloride;   Drug: sorafenib tosylate;   Drug: sunitinib malate;   Other: laboratory biomarker analysis;   Other: pharmacological study
19 Recruiting Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: pazopanib hydrochloride;   Other: placebo;   Procedure: quality-of-life assessment;   Other: questionnaire administration;   Other: pharmacological study
20 Recruiting Interleukin-2 in Metastatic Kidney Cancer
Conditions: Renal Cell Cancer Metastatic;   Kidney Cancer Metastatic
Intervention: Drug: Interleukin-2

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years